The US Food and Drug Administration recently approved a new treatment option for patients with early stage HER2-overexpressed/amplified breast cancer. For recommended dosage and common adverse events, read...
In a recent trial, researchers may have found a safe and effective alternative treatment for certain breast cancer patients who are not suited for systemic chemotherapy. For results of the trial, including...
After the results from a phase III randomized trial demonstrated its efficacy, the American Society of Clinical Oncology updated its guidelines to include a new genomic test. For information regarding...
The American College of Obstetricians and Gynecologists has recently released updated clinical guidelines on breast cancer screening in women facing average risk.
The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.
In a recent study, researchers examined whether a compound found in soy, isoflavone, could potentially reduce all-cause mortality risk in breast cancer survivors.
